Evidence map›Paper›PMID 34218684›Full record

ArticleClinical trials (London, England)2021

Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data.

Conner L Jackson, Kathryn Colborn, Dexiang Gao, Sangeeta Rao, Hannah C Slater, Sunil Parikh, Brian D Foy, John Kittelson

Open access · greenAbstract read
In one paragraph

Article in Clinical trials (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Conner L JacksonDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA.ORCID 0000-0002-3519-5667
Kathryn ColbornDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA.
Dexiang GaoDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Sangeeta RaoDepartment of Clinical Sciences, Colorado State University, Fort Collins, CO, USA.
Hannah C SlaterMalaria and NTDs, PATH, Seattle, WA, USA.
Sunil ParikhDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
Brian D FoyDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO, USA.
John KittelsonDepartment of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA.
Colorado School of Public Health · USColorado State University · USProgram for Appropriate Technology in Health · USUniversity of Colorado Denver · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malariaU01AI138910 · NIAID · COLORADO STATE UNIVERSITY · PI FOY, BRIAN DAVID, PARIKH, SUNIL · 2018 to 2022
$3.5M
NCATS NIH HHS UL1 TR001863NIAID NIH HHS U01 AI138910
6 · The paper itself

Abstract

backgroundCluster-randomized trials allow for the evaluation of a community-level or group-/cluster-level intervention. For studies that require a cluster-randomized trial design to evaluate cluster-level interventions aimed at controlling vector-borne diseases, it may be difficult to assess a large number of clusters while performing the additional work needed to monitor participants, vectors, and environmental factors associated with the disease. One such example of a cluster-randomized trial with few clusters was the "efficacy and risk of harms of repeated ivermectin mass drug administrations for control of malaria" trial. Although previous work has provided recommendations for analyzing trials like repeated ivermectin mass drug administrations for control of malaria, additional evaluation of the multiple approaches for analysis is needed for study designs with count outcomes.

methodsUsing a simulation study, we applied three analysis frameworks to three cluster-randomized trial designs (single-year, 2-year parallel, and 2-year crossover) in the context of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria. Mixed-effects models, generalized estimating equations, and cluster-level analyses were evaluated. Additional 2-year parallel designs with different numbers of clusters and different cluster correlations were also explored.

resultsMixed-effects models with a small sample correction and unweighted cluster-level summaries yielded both high power and control of the Type I error rate. Generalized estimating equation approaches that utilized small sample corrections controlled the Type I error rate but did not confer greater power when compared to a mixed model approach with small sample correction. The crossover design generally yielded higher power relative to the parallel equivalent. Differences in power between analysis methods became less pronounced as the number of clusters increased. The strength of within-cluster correlation impacted the relative differences in power.

conclusionRegardless of study design, cluster-level analyses as well as individual-level analyses like mixed-effects models or generalized estimating equations with small sample size corrections can both provide reliable results in small cluster settings. For 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria, we recommend a mixed-effects model with a pseudo-likelihood approximation method and Kenward-Roger correction. Similarly designed studies with small sample sizes and count outcomes should consider adjustments for small sample sizes when using a mixed-effects model or generalized estimating equation for analysis. Although the 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria is already underway as a parallel trial, applying the simulation parameters to a crossover design yielded improved power, suggesting that crossover designs may be valuable in settings where the number of available clusters is limited. Finally, the sensitivity of the analysis approach to the strength of within-cluster correlation should be carefully considered when selecting the primary analysis for a cluster-randomized trial.

Indexed as

IvermectinMalariaCluster AnalysisFollow-Up StudiesHumansMass Drug AdministrationRandomized Controlled Trials as TopicResearch DesignSample SizeIvermectinCluster-randomized trialscount datamalariasmall sample sizevector-borne diseases

Identifiers

PMID34218684
PMCPMC8478782
OpenAlexW3179529455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.